Table 1.

In vitro immunogenicity of TOP HLA-presented EOC antigens (MUC16, IDO1, LGALS1, KLK10, CRABP1/2) as well as antigens with additional HLA peptide presentation on normal tissues (MKI67, DDX5)

Tissues with HLA peptide presentation of source antigen (%)Tissues with HLA peptide presentation
HLASequenceProteinPositive/tested donorsEOCOvNBenign sourcesEOCOvNBenign sources
A*01STETSTVLYMUC160/333/42 (79)5/23 (22)0/85 (0)300
A*02IITEVITRLMUC163/10100
A*02KMISAIPTLMUC164/6300
A*03SVLADLVTTKMUC160/1100
A*11STSQEIHSATKMUC162/6100
A*11GTSGTPVSKMUC160/5100
A*24TYSEKTTLFMUC163/3510
A*24QFITSTNTFMUC161/2100
A*24AVTNVRTSIMUC161/3200
A*25EVITSSRTTIMUC161/1200
A*25EVISSRGTSMMUC161/3300
A*25EVTSSGRTSIMUC162/3300
A*25ETILTFHAFMUC162/2500
B*07SPHPVTALLMUC161/1400
B*07SPQNLRNTLMUC162/3400
B*07TPGNRAISLMUC165/5610
B*07SPLFQRSSLMUC161/3100
B*07SPHPVTALLMUC161/2400
B*07LPHSEITTLMUC161/3200
B*07TPGGTRQSLMUC160/3730
B*07SPSKAFASLMUC163/3920
B*07VPRSAATTLMUC162/3300
B*15SQGFSHSQMMUC164/5100
B*15FQRQGQTALMUC161/6100
B*18TETEAIHVFMUC161/1400
B*27ERSPVIQTLMUC161/2100
B*51DPYKATSAVMUC163/3710
B*51DALVLKTVMUC161/3500
A*03RSYHLQIVTKIDO11/112/42 (29)4/23 (17)0/85 (0)520
A*11RSYHLQIVTKIDO11/1520
A*24RYMPPAHRNFIDO14/4200
B*07NPKAFFSVLIDO13/5100
A*25EVAPDAKSFLGALS11/111/42 (26)1/23 (4)0/85 (0)510
A*02RTTEINFKVCRABP1/21/215/42 (36)0/23 (0)0/85 (0)900
A*02RALAKLLPLKLK102/29/42 (21)0/23 (0)0/85 (0)700
A*11SSKSQTEVPKMKI 670/521/42 (50)0/23 (0)14/85 (16)005
B*08TPKEKAQALMKI 670/5200
A*02YLLPAIVHIDDX 50/529/42 (69)18/23 (78)63/85 (74)231336